In this analysis, clinical characteristics, real-world treatment patterns, and health outcomes among patients with germline BRCA1/2-mutated, HER2-negative ABC in the US were evaluated in order to contextualize the results of relevant clinical trials and determine the extent of unmet need among these patients in the routine clinical-practice setting. This evidence concerns the gene BRCA1 and aneurysmal bone cyst.